JOHNSON & JOHNSON Reports Strong Financial Results for Q2 of FY2023
July 25, 2023
☀️Earnings Overview
For the second quarter of FY2023, JOHNSON & JOHNSON ($NYSE:JNJ) reported total revenue of USD 25.5 billion, a 6.3% increase compared to the same quarter in FY2022. Net income increased 6.9% to USD 5.1 billion year over year.
Market Price
On Thursday, JOHNSON & JOHNSON reported strong financial results for the second quarter of its financial year 2023. The stock opened at $161.9 and closed at $168.4, a rise of 6.1% from the prior closing price of $158.7. The strong financial performance is attributed to multiple factors. This was partly due to the company’s focus on expanding into new markets and increasing its product portfolio.
Finally, the company saw significant improvements in its cash flow in the second quarter. This strong cash flow has allowed the company to invest in new initiatives and expand its operations in both domestic and global markets. The stock opened at $161.9 and closed at $168.4, a rise of 6.1% from its prior closing price of $158.7, which bodes well for the future prospects of the company. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for JNJ. More…
| Total Revenues | Net Income | Net Margin |
| 97.77k | 13.05k | 12.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for JNJ. More…
| Operations | Investing | Financing |
| 23.42k | -6.19k | -18.02k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for JNJ. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 179.23k | 108.96k | 27.04 |
Key Ratios Snapshot
Some of the financial key ratios for JNJ are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 6.7% | 6.9% | 24.3% |
| FCF Margin | ROE | ROA |
| 24.3% | 21.1% | 8.3% |
Analysis
At GoodWhale, we recently conducted an analysis on JOHNSON & JOHNSON’s wellbeing. Based on our Risk Rating, it is a medium risk investment in terms of financial and business aspects. We have also detected two risk warnings in balance sheet, non financial. By registering with us, you can access the full analysis and understand the potential risks associated with JOHNSON & JOHNSON’s investments. Our aim is to provide investors with the most comprehensive information to make informed decisions when investing their money. With our detailed analysis, you can understand the current financial stability of JOHNSON & JOHNSON and make informed decisions about the best way to allocate your money. Register with us today to access our full report and gain a better understanding of the potential risks associated with this company. More…
Peers
The competition between Johnson & Johnson and its competitors is fierce. AstraZeneca PLC, Pfizer Inc, and BioNTech SE are all major players in the pharmaceutical industry, and they are all vying for a piece of the pie. Johnson & Johnson is a well-established company with a long history of success, but its competitors are not to be underestimated. They are all large, well-funded companies with a lot to lose if they don’t win the competition.
– AstraZeneca PLC ($LSE:AZN)
AstraZeneca PLC is a biopharmaceutical company with a market cap of 152.13B as of 2022. The company focuses on the discovery, development, and commercialization of small molecule drugs in the areas of oncology, cardiovascular, and renal & metabolism. The company’s ROE for the year ended December 31, 2020 was -0.94%.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc is a pharmaceutical company with a market cap of 240.55B as of 2022. The company has a return on equity of 24.63%. Pfizer Inc is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The company’s products include prescription and over-the-counter medicines, vaccines, and biologic therapies.
– BioNTech SE ($NASDAQ:BNTX)
BioNTech SE is a German biotech company founded in 2008 that focuses on the development of Innovation therapies against cancer and other serious diseases. The company has a market cap of 32.91B as of 2022 and a Return on Equity of 71.82%. BioNTech’s mission is to revolutionize the treatment of cancer and other serious diseases by leveraging the power of the immune system. The company is developing a portfolio of immunotherapy products based on its proprietary mRNA technology platform.
Summary
Johnson & Johnson reported strong financial results for the second quarter of FY2023, with total revenue of USD 25.5 billion, representing a 6.3% year-on-year increase, and net income of USD 5.1 billion, up 6.9%. This positive news caused the stock price to rise on the same day. Investors should consider J&J a strong pick, especially due to its strong balance sheet and consistent earnings growth.
In addition, the company has ample cash on hand to invest in potential growth opportunities. With competitive products and a solid commitment to innovation, J&J looks to be a sound investment for the long-term.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
